Clinical Implications of Opioid Pharmacogenomics in Patients with Cancer

Teunissen S.C. , Wesker W. , Kruitwagen C. . Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage. 2007; 34(1): 94–104.

van den Beuken-van Everdingen M.H. , de Rijke J.M. , Kessels A.G. . Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007; 18(9): 1437–1449.

Hui D. , Bruera E. . A personalized approach to assessing and managing pain in patients with cancer. J Clin Oncol. 2014; 32(16): 1640–1646.

Halabi S. , Vogelzang N.J. , Kornblith A.B. . Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol. 2008; 26(15): 2544–2549.

Quinten C. , Coens C. , Mauer M. . Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol. 2009; 10(9): 865–871.

Smith T.J. , Staats P.S. , Deer T. ; Implantable Drug Delivery Systems Study Group. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol. 2002; 20(19): 4040–4049.

Herndon JE II , Fleishman S. , Kornblith A.B. . Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma? Cancer. 1999; 85(2): 333–340.

Zhao F. , Chang V.T. , Cleeland C. . Determinants of pain severity changes in ambulatory patients with cancer: an analysis from Eastern Cooperative Oncology Group trial E2Z02. J Clin Oncol. 2014; 32(4): 312–319.

Mercadante S. , Porzio G. , Gebbia V. . New opioids. J Clin Oncol. 2014; 32(16): 1671–1676.

Slatkin N.E. . Opioid switching and rotation in primary care: implementation and clinical utility. Curr Med Res Opin. 2009; 25(9): 2133–2150.

Vardy J. , Agar M. . Nonopioid drugs in the treatment of cancer pain. J Clin Oncol. 2014; 32(16): 1677–1690.

Kleine-Brueggeney M. , Musshoff F. , Stuber F. . Pharmacogenetics in palliative care. Forensic Sci Int. 2010; 203 (1-3): 63–70.

Wiffen P.J. , Derry S. , Moore R.A. . Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain. Cochrane Database Syst Rev. 2014; 5: CD011056.

Hajj A. , Khabbaz L. , Laplanche J.L. . Pharmacogenetics of opiates in clinical practice: the visible tip of the iceberg. Pharmacogenomics. 2013; 14(5): 575–585.

Nielsen L.M. , Olesen A.E. , Branford R. . Association between human pain-related genotypes and variability in opioid analgesia: an updated review. Pain Pract. 2015; 15(6): 580–594.

Lötsch J. , von Hentig N. , Freynhagen R. . Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenet Genomics. 2009; 19(6): 429–436.

Campa D. , Gioia A. , Tomei A. . Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther. 2008; 83(4): 559–566.

Hung C.C. , Chiou M.H. , Huang B.H. . Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients. Pharmacogenomics. 2011; 12(11): 1525–1533.

Smith M.T. , Muralidharan A. . Pharmacogenetics of pain and analgesia. Clin Genet. 2012; 82(4): 321–330.

Rollason V. , Samer C. , Piguet V. . Pharmacogenetics of analgesics: toward the individualization of prescription. Pharmacogenomics. 2008; 9(7): 905–933.

Crews K.R. , Gaedigk A. , Dunnenberger H.M. ; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther. 2014; 95(4): 376–382.

Andreassen T.N. , Eftedal I. , Klepstad P. . Do CYP2D6 genotypes refect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study. Eur J Clin Pharmacol. 2012; 68(1): 55–64.

Gasche Y. , Daali Y. , Fathi M. . Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med. 2004; 351(27): 2827–2831.

Wilkinson G.R. . Drug metabolism and variability among patients in drug response. N Engl J Med. 2005; 352(21): 2211–2221.

Ravindranathan A. , Joslyn G. , Robertson M. . Functional characterization of human variants of the mu-opioid receptor gene. Proc Natl Acad Sci U S A. 2009; 106(26): 10811–10816.

Kasai S. , Ikeda K. . Pharmacogenomics of the human micro-opioid receptor. Pharmacogenomics. 2011; 12(9): 1305–1320.

Branford R. , Droney J. , Ross J.R. . Opioid genetics: the key to personalized pain control? Clin Genet. 2012; 82(4): 301–310.

Reyes-Gibby C.C. , Shete S. , Rakvåg T. . Exploring joint effects of genes and the clinical effcacy of morphine for cancer pain: OPRM1 and COMT gene. Pain. 2007; 130 (1-2): 25–30.

Klepstad P. , Rakvåg T.T. , Kaasa S. . The 118 A >G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand. 2004; 48(10): 1232–1239.

Ross J.R. , Rutter D. , Welsh K. . Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics J. 2005; 5(5): 324–336.

Klepstad P. , Fladvad T. , Skorpen F. ; European Palliative Care Research Collaborative (EPCRC); European Association for Palliative Care Research Network. Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients. Pain. 2011; 152(5): 1139–1145.

Andersen S. , Skorpen F. . Variation in the COMT gene: implications for pain perception and pain treatment. Pharmacogenomics. 2009; 10(4): 669–684.

Belfer I. , Segall S. . COMT genetic variants and pain. Drugs Today (Barc). 2011; 47(6): 457–467.

Rakvåg T.T. , Klepstad P. , Baar C. . The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain. 2005; 116 (1-2): 73–78.

Rakvåg T.T. , Ross J.R. , Sato H. . Genetic variation in the catechol-O-methyltransferase (COMT) gene and morphine requirements in cancer patients with pain. Mol Pain. 2008; 4: 64.

Ross J.R. , Riley J. , Taegetmeyer A.B. . Genetic variation and response to morphine in cancer patients: catechol-O-methyltransferase and multidrug resistance-1 gene polymorphisms are associated with central side effects. Cancer. 2008; 112(6): 1390–1403.

Stamer U.M. , Musshoff F. , Kobilay M. . Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. Clin Pharmacol Ther. 2007; 82(1): 41–77.

Poulsen L. , Arendt-Nielsen L. , Brøsen K. . The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther. 1996; 60(6): 636–644.

Stamer U.M. , Lehnen K. , Höthker F. . Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain. 2003; 105 (1-2): 231–238.

Vuilleumier P.H. , Stamer U.M. , Landau R. . Pharmacogenomic considerations in opioid analgesia. Pharmgenomics Pers Med. 2012; 5: 73–87.

Takashina Y. , Naito T. , Mino Y. . Impact of CYP3A5 and ABCB1 gene polymorphisms on fentanyl pharmacokinetics and clinical responses in cancer patients undergoing conversion to a transdermal system. Drug Metab Pharmacokinet. 2012; 27(4): 414–421.

Bell G.C. , Crews K.R. , Wilkinson M.R. . Development and use of active clinical decision support for preemptive pharmacogenomics. J Am Med Inform Assoc. 2014; 21 (e1): e93–e99.